| Project/Area Number |
20K21671
|
|---|
| Research Category |
Grant-in-Aid for Challenging Research (Exploratory)
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Medium-sized Section 57:Oral science and related fields
|
|---|
| Research Institution | Niigata University |
|---|
Principal Investigator |
Terao Yutaka 新潟大学, 医歯学系, 教授 (50397717)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
伊東 孝祐 新潟大学, 自然科学系, 准教授 (20502397)
土門 久哲 新潟大学, 医歯学系, 准教授 (00594350)
前川 知樹 新潟大学, 医歯学系, 研究教授 (50625168)
|
|---|
| Project Period (FY) |
2020-07-30 – 2022-03-31
|
| Project Status |
Completed (Fiscal Year 2021)
|
| Budget Amount *help |
¥6,500,000 (Direct Cost: ¥5,000,000、Indirect Cost: ¥1,500,000)
Fiscal Year 2021: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2020: ¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
|
|---|
| Keywords | MRSA |
|---|
| Outline of Research at the Start |
抗菌薬に耐性を示す黄色ブドウ球菌（MRSA）が，各国で数得多くの院内感染を引き起こし問題となっている．しかしながら，耐性菌の新薬開発研究は，国内外で不十分という現実に直面している．そこで本研究では，CRISPR-Casゲノム編集技術を応用し，MRSAの耐性因子PBP2’等の遺伝子を特異的に削除するDNA製抗菌薬の開発に挑戦する．
|
| Outline of Final Research Achievements |
The estimated death by MRSA infections in Japan is more than 10,000 per year. Furthermore, in the latest infection control surveillance, the MRSA detection rate at domestic medical institutions was approximately 100%. Nevertheless, research and development of new drugs against drug-resistant bacteria is facing the reality of inadequacy. Therefore, in this present study, we applied CRISPR-Cas genome editing technology to develop a DNA antibacterial drug that specifically deletes the resistance factor PBP2' in MRSA. By using DNA (CRISPR-Cas expression plasmid) as a material, the possibility of side reactions will be low, and the drug target will be able to exchange simply by changing the guide RNA sequence according to the evolution of resistance. This was because it could be an antibacterial drug.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究では，歯科臨床にも関連深いMRSA対策を足掛りとし，成果の波及を期すのは，WHOが予測する2050年における世界の耐性菌問題である．将来の耐性菌により推計される被害，すなわち“年間約1兆円の社会的・経済的損失と約1000万の人命（WHO試算）”を救う挑戦であり，そのための「芽生え期」の計画である．また，耐性菌を生まない万能抗菌薬を求める既存の研究から，新たな耐性菌の出現を前提とする着想に切り替え，その次の対策を事前想定したオンリーワンの研究でもある．
|
